Analytical Lens: Exploring Revance Therapeutics Inc (RVNC)’s Financial Story Through Ratios

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Revance Therapeutics Inc (NASDAQ: RVNC) was $2.70 for the day, down -6.90% from the previous closing price of $2.90. In other words, the price has decreased by -$6.90 from its previous closing price. On the day, 1.28 million shares were traded. RVNC stock price reached its highest trading level at $2.88 during the session, while it also had its lowest trading level at $2.68.

Ratios:

Our analysis of RVNC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.64 and its Current Ratio is at 5.37.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.

On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.

Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 16 ’24 when Jordan Erica sold 2,392 shares for $3.80 per share. The transaction valued at 9,096 led to the insider holds 114,864 shares of the business.

Schilke Tobin sold 9,361 shares of RVNC for $47,204 on Mar 18 ’24. The CFO now owns 192,666 shares after completing the transaction at $5.04 per share. On Mar 18 ’24, another insider, Sjuts Dustin S, who serves as the President of the company, sold 9,211 shares for $5.04 each. As a result, the insider received 46,446 and left with 167,550 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 282012320 and an Enterprise Value of 480715968. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19. Its current Enterprise Value per Revenue stands at 2.001 whereas that against EBITDA is -2.27.

Stock Price History:

Over the past 52 weeks, RVNC has reached a high of $32.45, while it has fallen to a 52-week low of $2.59. The 50-Day Moving Average of the stock is -26.73%, while the 200-Day Moving Average is calculated to be -63.85%.

Shares Statistics:

RVNC traded an average of 1.91M shares per day over the past three months and 1742080 shares per day over the past ten days. A total of 104.45M shares are outstanding, with a floating share count of 95.32M. Insiders hold about 8.74% of the company’s shares, while institutions hold 85.40% stake in the company. Shares short for RVNC as of 1715731200 were 12490424 with a Short Ratio of 6.54, compared to 1713139200 on 11625272. Therefore, it implies a Short% of Shares Outstanding of 12490424 and a Short% of Float of 13.73.

Most Popular